Operator

Good day, and thank you for standing by. Welcome to the Addex Therapeutics Full Year 2025 Financial Results and Corporate Update Conference Call and Webcast. [Operator Instructions] Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your first speaker today, Tim Dyer. Please go ahead.

Timothy Dyer
Co-Founder, CEO & Director

Thank you. Hello, everyone. I would like to thank you all for attending our 2025 full year financial results conference call. I'm here with Misha Kalinichev, our Head of Translational Science, who will provide an update on our R&D programs.

I draw your attention to the press release and the financial statements issued earlier today, which are available on our website. I also draw your attention to our disclaimer. We will be making certain forward-looking statements that are based on the knowledge we have today.

I will start this conference call by giving a quick overview of our recent activities and achievements before reviewing our pipeline. I will then hand over to Misha, who will review in more detail our mGlu5 negative allosteric modulator program for brain injury recovery and the GABAB positive allosteric modulator preclinical program for cough. I will then review our 2025 full year financial results. Following that, we will open the call for Q&A.

So 2025 has seen several important achievements across our pipeline. We made excellent progress in our GABAB PAM chronic cough program as we continue to complete preclinical characterization of our selective compound. We recently announced robust antitussive activity in a nonhuman primate chronic cough model as well as solid antitussive activity